Effect of Nalmefene 20 and 80mg on the corrected QT interval and T-wave morphology: A randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study

Clinical Drug Investigation

Volumn 31, Issue 11, 2011, Pages 799-811

  Matz, Jørgen ^a   Graff, Claus ^b   Vainio, Petri J ^c   Kallio, Antero ^c   Højer, Astrid Maria ^a   Struijk, Johannes J ^b   Kanters, Jørgen K ^d,e,f   Andersen, Mads P ^b   Toft, Egon ^b  

^a H LUNDBECK A S   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Biotie Therapies Corp   (Finland)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alcoholism; Arrhythmias; Nalmefene; Opioid receptor antagonists; QT interval prolongation

Indexed keywords

MOXIFLOXACIN; NALMEFENE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HALLUCINATION; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HUMAN; INSOMNIA; LETHARGY; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; T WAVE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; ANTI-INFECTIVE AGENTS; ARRHYTHMIAS, CARDIAC; AZA COMPOUNDS; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GUIDELINES AS TOPIC; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PLACEBOS; PROSPECTIVE STUDIES; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053536581     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/bf03256919     Document Type: Article

References (31)

1. Osborn MD, Lowery JJ, Skorput AG, et al. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci 2010 Apr 10; 86 (15-16): 624-30
2. Ingman K, Hagelberg N, Aalto S, et al. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacol 2005 Dec; 30 (12): 2245-53 (Pubitemid 41643976)
3. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994 Oct; 18 (5): 1162-7 (Pubitemid 24345524)
4. Mason BJ, Salvato FR, Williams LD, et al. A doubleblind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999 Aug; 56 (8): 719-24 (Pubitemid 29357733)
5. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebocontrolled multicenter study. Alcohol Clin Exp Res 2007 Jul; 31 (7): 1179-87 (Pubitemid 46934385)
6. Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004 Aug; 24 (4): 421-8 (Pubitemid 38944141)
7. ICH Harmonised Tripartite Guideline. ICH E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. May 2005 [online]. Available from URL http://www.ich.org/guidelines/the- clinical-evaluation-of-qtqtc-interval-prolon gation-and-proarrhythmic-potential- for-non-antiarrh.html [Acccessed 2011 Jul 1]
8. Donado E, Izquierdo I, Perez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a thorough QT/QTc study performed according to ICH guidelines. Br J Clin Pharmacol 2010 Apr; 69 (4): 401-10
9. Oh C, Rengelshausen J, Mangold B, et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther 2010 Oct; 48 (10): 678-87
10. Moore KA, Callahan TS, Maison-Blanche P, et al. Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding. Expert Opin Pharmacother 2010 Oct; 11 (14): 2281-90
11. Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol 2010 Jul; 70 (1): 24-33
12. Malhotra B, Wood N, Sachse R, et al. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010 May; 48 (5): 309-18
13. Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf 2010 Jan 1; 33 (1): 1-14
14. Chapel S, Hutmacher MM, Haig G, et al. Exposureresponse analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009 Nov; 49 (11): 1297-308
15. Kubitza D, Mueck W, Becka M. Randomized, doubleblind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31 (1): 67-77
16. Graff C, Matz J, Christensen EB, et al. Quantitative analysis of T-wave morphology increases confidence in druginduced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. J Clin Pharmacol 2009 Nov; 49 (11): 1331-42
17. Haarmark C, Graff C, Andersen MP, et al. Reference values of electrocardiogram repolarization variables in a healthy population. J Electrocardiol 2010 Jan; 43 (1): 31-9
18. Graff C, AndersenMP, Xue JQ, et al. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Saf 2009; 32 (7): 599-611
19. Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009 Oct; 19 (10): 702-7
20. Andersen MP, Xue JQ, Graff C, et al. New descriptors of T-wave morphology are independent of heart rate. J Electrocardiol 2008 Nov; 41 (6): 557-61
21. Graff C, Struijk JJ, Matz J, et al. Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. Clin Pharmacol Ther 2010 Jul; 88 (1): 88-94
22. Kanters JK, Fanoe S, Larsen LA, et al. T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome. Heart Rhythm 2004 Sep; 1 (3): 285-92 (Pubitemid 39549756)
23. Lupoglazoff JM, Denjoy I, Berthet M, et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations. Circulation 2001 Feb 27; 103 (8): 1095-101 (Pubitemid 32200183)
24. Dalen P, Vik T, Alverlind S, et al. Evaluation of the effects of AZD3480 on cardiac repolarization: a thorough QT/QTc study using moxifloxacin as a positive control. Clin Pharmacol Ther 2010 Oct; 88 (4): 532-9
25. Yan LK, Zhang J, Ng MJ, et al. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat 2010 May; 20 (3): 497-507
26. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008 Oct; 84 (4): 475-80
27. Matzke GR, Frye RF, Alexander AC, et al. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. J Clin Pharmacol 1996 Feb; 36 (2): 144-51 (Pubitemid 26082400)
28. Frye RF, Matzke GR, Schade R, et al. Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin Pharmacol Ther 1997 Jan; 61 (1): 15-23 (Pubitemid 27072880)
29. Biotie Therapies BTT31-PD079-R01. Nalmefene: effect on HERG-1 tail currents recorded from stably transfected HEK 293 cells. 2005 (unpublished preclinical study report)
30. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 2011; 129 (2): 109-19
31. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006 Feb; 163 (2): 303-12 (Pubitemid 44480852)